These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. (111)In-labeled trastuzumab (Herceptin) modified with nuclear localization sequences (NLS): an Auger electron-emitting radiotherapeutic agent for HER2/neu-amplified breast cancer. Costantini DL; Chan C; Cai Z; Vallis KA; Reilly RM J Nucl Med; 2007 Aug; 48(8):1357-68. PubMed ID: 17631548 [TBL] [Abstract][Full Text] [Related]
23. Tumor uptake and tumor/blood ratios for [ Al-Saden N; Cai Z; Reilly RM Nucl Med Biol; 2018 Dec; 67():43-51. PubMed ID: 30390575 [TBL] [Abstract][Full Text] [Related]
24. Multifunctional targeted therapy system based on (99m) Tc/(177) Lu-labeled gold nanoparticles-Tat(49-57)-Lys(3) -bombesin internalized in nuclei of prostate cancer cells. Jiménez-Mancilla N; Ferro-Flores G; Santos-Cuevas C; Ocampo-García B; Luna-Gutiérrez M; Azorín-Vega E; Isaac-Olivé K; Camacho-López M; Torres-García E J Labelled Comp Radiopharm; 2013 Nov; 56(13):663-71. PubMed ID: 25196028 [TBL] [Abstract][Full Text] [Related]
25. Clinical Dose Preparation of [ Menon SR; Mitra A; Chakraborty A; Tawate M; Sahu S; Rakshit S; Gaikwad S; Dhotre G; Damle A; Banerjee S Cancer Biother Radiopharm; 2022 Jun; 37(5):384-402. PubMed ID: 35575711 [No Abstract] [Full Text] [Related]
26. 111In-labeled immunoconjugates (ICs) bispecific for the epidermal growth factor receptor (EGFR) and cyclin-dependent kinase inhibitor, p27Kip1. Cornelissen B; Kersemans V; McLarty K; Tran L; Reilly RM Cancer Biother Radiopharm; 2009 Apr; 24(2):163-73. PubMed ID: 19409037 [TBL] [Abstract][Full Text] [Related]
27. [Novel HER2-Targeted Therapy Combined with Gold Nanoparticles]. Kubota T; Kuroda S; Morihiro T; Tazawa H; Kagawa S; Fujiwara T Gan To Kagaku Ryoho; 2016 Oct; 43(10):1237-1239. PubMed ID: 27760946 [TBL] [Abstract][Full Text] [Related]
28. Molecularly targeted gold nanoparticles enhance the radiation response of breast cancer cells and tumor xenografts to X-radiation. Chattopadhyay N; Cai Z; Kwon YL; Lechtman E; Pignol JP; Reilly RM Breast Cancer Res Treat; 2013 Jan; 137(1):81-91. PubMed ID: 23160926 [TBL] [Abstract][Full Text] [Related]
29. Dose-dependent cell cycle arrest and apoptosis in HER2 breast cancer cells by Sharma R; Kameswaran M; Pandey U; Dash A J Cancer Res Ther; 2020; 16(6):1426-1434. PubMed ID: 33342808 [TBL] [Abstract][Full Text] [Related]
30. Evaluation of an Anti-HER2 Nanobody Labeled with Pruszynski M; D'Huyvetter M; Bruchertseifer F; Morgenstern A; Lahoutte T Mol Pharm; 2018 Apr; 15(4):1457-1466. PubMed ID: 29502411 [TBL] [Abstract][Full Text] [Related]
31. A comparison of non-biologically active truncated EGF (EGFt) and full-length hEGF for delivery of Auger electron-emitting 111In to EGFR-positive breast cancer cells and tumor xenografts in athymic mice. Panosa C; Fonge H; Ferrer-Batallé M; Menéndez JA; Massaguer A; De Llorens R; Reilly RM Nucl Med Biol; 2015 Dec; 42(12):931-8. PubMed ID: 26385534 [TBL] [Abstract][Full Text] [Related]
32. Development of Lu-177-trastuzumab for radioimmunotherapy of HER2 expressing breast cancer and its feasibility assessment in breast cancer patients. Bhusari P; Vatsa R; Singh G; Parmar M; Bal A; Dhawan DK; Mittal BR; Shukla J Int J Cancer; 2017 Feb; 140(4):938-947. PubMed ID: 27813061 [TBL] [Abstract][Full Text] [Related]
33. Fluorescent, Plasmonic, and Radiotherapeutic Properties of the Mendoza-Nava H; Ferro-Flores G; Ramírez FM; Ocampo-García B; Santos-Cuevas C; Azorín-Vega E; Jiménez-Mancilla N; Luna-Gutiérrez M; Isaac-Olivé K Mol Imaging; 2017 Jan; 16():1536012117704768. PubMed ID: 28654384 [TBL] [Abstract][Full Text] [Related]
34. Trastuzumab-modified DM1-loaded nanoparticles for HER2 Rong L; Zhou S; Liu X; Li A; Jing T; Liu X; Zhang Y; Cai S; Tang X Artif Cells Nanomed Biotechnol; 2018 Dec; 46(8):1708-1718. PubMed ID: 29069935 [TBL] [Abstract][Full Text] [Related]
35. Metal-Chelating Polymers (MCPs) with Zwitterionic Pendant Groups Complexed to Trastuzumab Exhibit Decreased Liver Accumulation Compared to Polyanionic MCP Immunoconjugates. Liu P; Boyle AJ; Lu Y; Adams J; Chi Y; Reilly RM; Winnik MA Biomacromolecules; 2015 Nov; 16(11):3613-23. PubMed ID: 26469142 [TBL] [Abstract][Full Text] [Related]
36. Targeted dual degradation of HER2 and EGFR obliterates oncogenic signaling, overcomes therapy resistance, and inhibits metastatic lesions in HER2-positive breast cancer models. Yang L; Bhattacharya A; Peterson D; Li Y; Liu X; Marangoni E; Robila V; Zhang Y Drug Resist Updat; 2024 May; 74():101078. PubMed ID: 38503142 [TBL] [Abstract][Full Text] [Related]
37. Improvement of the Effectiveness of HER2+ Cancer Therapy by Use of Doxorubicin and Trastuzumab Modified Radioactive Gold Nanoparticles. Żelechowska-Matysiak K; Salvanou EA; Bouziotis P; Budlewski T; Bilewicz A; Majkowska-Pilip A Mol Pharm; 2023 Sep; 20(9):4676-4686. PubMed ID: 37607353 [TBL] [Abstract][Full Text] [Related]
38. Gibbens-Bandala B; Morales-Avila E; Ferro-Flores G; Santos-Cuevas C; Meléndez-Alafort L; Trujillo-Nolasco M; Ocampo-García B Mater Sci Eng C Mater Biol Appl; 2019 Dec; 105():110043. PubMed ID: 31546458 [TBL] [Abstract][Full Text] [Related]
39. Radioimmunotherapy of PANC-1 human pancreatic cancer xenografts in NOD/SCID or NRG mice with Panitumumab labeled with Auger electron emitting, Aghevlian S; Cai Z; Hedley D; Winnik MA; Reilly RM EJNMMI Radiopharm Chem; 2020 Nov; 5(1):22. PubMed ID: 33169241 [TBL] [Abstract][Full Text] [Related]
40. Trastuzumab- and Fab' fragment-modified curcumin PEG-PLGA nanoparticles: preparation and evaluation in vitro and in vivo. Duan D; Wang A; Ni L; Zhang L; Yan X; Jiang Y; Mu H; Wu Z; Sun K; Li Y Int J Nanomedicine; 2018; 13():1831-1840. PubMed ID: 29606874 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]